Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Samsung
Elon Musk
Google
Space News
Motorola
Android 13
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / Technology News / Moderna's COVID-19 vaccine shows 'positive' results in human trials
Technology

Moderna's COVID-19 vaccine shows 'positive' results in human trials

Moderna's COVID-19 vaccine shows 'positive' results in human trials
Written by Shubham Sharma
May 18, 2020, 11:36 pm 3 min read
Moderna's COVID-19 vaccine shows 'positive' results in human trials

Moderna Therapeutics, one of the select few companies working on a COVID-19 vaccine, has revealed positive results from early-stage trials of its formula. The company has announced that its vaccine candidate was able to generate antibody responses in all the participants who had volunteered for its test. Here's all you need to know about it.

Study
Stage I trial started in March

Back in March, Moderna became the first US company to start human trials of a COVID-19 vaccine candidate called mRNA-1273. The experimental vaccine was given in three separate doses - 25 micrograms, 100 micrograms, and 250 micrograms - to 45 people (each dose for 15) at a gap of approximately 28 days. Then, the participants were closely monitored to see how it worked.

Results
Results show antibodies in all volunteers

Now, the early results revealed by Moderna show that the vaccine has produced detectable antibodies in all the volunteers, with dose-dependent increment in immunogenicity. The company says that the participants who got the 25 micrograms shot generated antibodies at levels seen in blood samples of recovered COVID-19 patients, while the 100 micrograms group had antibodies that "significantly exceeded levels" seen in recovered cases.

Detail
Some volunteers produced neutralizing antibodies

While the data of the third 250 micrograms group was not available, the team did note that the vaccine candidate was able to produce neutralizing antibodies in at least eight of the participants (four each from 25 and 100 micrograms group). Now, this is a great development, given that neutralizing antibodies play a major role in fighting off viruses like the novel coronavirus.

Animal trials
Antibody levels consistent with animal trials

Moderna also notes that the level of neutralizing antibodies generated from the vaccine in humans is consistent with those seen in animals. The company had worked with the NIH to test the vaccine on mice, which were able to generate enough antibodies to fight off the novel coronavirus and prevent it from replicating in the lungs.

Quote
Here's what Moderna chief medical officer Dr. Tal Zaks said

"These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25. These data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease."

Need
More data still needed to confirm full efficacy

The results are promising but the team still needs more data, especially on the antibodies, to confirm mRNA-1273's efficacy/safety. For this, it will be conducting Phase-2 trials, where the vaccine will be tested on 600 adults. The results of these tests will be available around July, following which Moderna will start Phase-3 trials, lining up the vaccine for approval for use in early 2021.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Shubham Sharma
Shubham Sharma
Twitter
Editor with over five years of experience in covering all things science, consumer tech, space tech, AI, infosec, and business. A commerce graduate from University of Lucknow. I have been handling Tech beat at NewsBytes since 2018.
Latest
United States of America
Moderna Therapeutics
Moderna Inc
Latest
Manga lashes: A step-by-step guide to get this anime-inspired look
Manga lashes: A step-by-step guide to get this anime-inspired look Lifestyle
Asia Cup 2022 Qualifiers: All you need to know
Asia Cup 2022 Qualifiers: All you need to know Sports
5 best jeans for different body shapes
5 best jeans for different body shapes Lifestyle
Here's how you can choose the perfect cleanser
Here's how you can choose the perfect cleanser Lifestyle
Did Somy Ali label Salman Khan a 'women beater'?
Did Somy Ali label Salman Khan a 'women beater'? Entertainment
United States of America
Long road ahead: Staggering 500-day wait for US visa
Long road ahead: Staggering 500-day wait for US visa World
'He attacked Islam': Salman Rushdie's attacker 'surprised' author is alive
'He attacked Islam': Salman Rushdie's attacker 'surprised' author is alive World
National Ice Cream Pie Day 2022: History, celebrations and more
National Ice Cream Pie Day 2022: History, celebrations and more Lifestyle
US: 99-year-old woman welcomes her 100th great-grandchild
US: 99-year-old woman welcomes her 100th great-grandchild World
Salman Rushdie taken off ventilator, talking; accused pleads not guilty
Salman Rushdie taken off ventilator, talking; accused pleads not guilty World
More News
Moderna Therapeutics
Moderna's COVID-19 vaccine found to be 95% effective: Details here
Moderna's COVID-19 vaccine found to be 95% effective: Details here Technology
Zydus Cadila's COVID-19 vaccine found safe, going into Phase-2 trial
Zydus Cadila's COVID-19 vaccine found safe, going into Phase-2 trial India
Chinese hackers targeted COVID-19 vaccine maker Moderna: Report
Chinese hackers targeted COVID-19 vaccine maker Moderna: Report World
Moderna's COVID-19 vaccine goes into final human trial stage
Moderna's COVID-19 vaccine goes into final human trial stage World
NewsBytes Briefing: Snap's revenue grows; Moderna's vaccine won't be cheap
NewsBytes Briefing: Snap's revenue grows; Moderna's vaccine won't be cheap Technology
More News
Moderna Inc
Bharat Biotech completes third-phase of intranasal COVID-19 vaccine trials
Bharat Biotech completes third-phase of intranasal COVID-19 vaccine trials India
Moderna COVID-19 vaccine produces lasting immune response: Study
Moderna COVID-19 vaccine produces lasting immune response: Study Technology
Japan suspends 1.63mn Moderna vaccine doses after contamination found
Japan suspends 1.63mn Moderna vaccine doses after contamination found World
No sign of Pfizer, Moderna vaccines in breast milk: Study
No sign of Pfizer, Moderna vaccines in breast milk: Study Technology
India offered 7.5mn doses of Moderna vaccine under COVAX program
India offered 7.5mn doses of Moderna vaccine under COVAX program India
More News
Next News Article
Next News Article

Love Technology news?

Subscribe to stay updated.

Science Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022